

**RUBRA MEDICAMENTS LIMITED**

**Statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2022**

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceeding 3 months ended	Figures for corresponding 3 months ended in the previous year	Figures for current period ended	Figures for previous period ended
		31-Mar-22	31-Dec-21	31-Mar-21	31-Mar-22	31-Mar-21
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue from Operations	62.00	43.50	29.75	201.11	48.50
II	Other Income	0.08	0.00	0.00	0.08	0.00
III	<b>Total Income (I + II)</b>	<b>62.08</b>	<b>43.50</b>	<b>29.75</b>	<b>201.19</b>	<b>48.50</b>
IV	<b>Expenses:</b>					
	Cost of Materials Consumed	0.00	0.00	0.00	0.00	0.00
	Purchases of Stock in Trade	0.00	1.92	8.26	51.99	8.26
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00	0.00
	Employee benefits Expense	12.21	2.07	16.45	22.57	19.54
	Finance Costs	0.00	0.00	0.03	0.01	0.04
	Depreciation & amortisation expense	0.04	0.04	0.04	0.16	0.16
	Other Expenses	50.90	43.55	4.27	128.69	19.68
	<b>Total Expenses (IV)</b>	<b>63.15</b>	<b>47.58</b>	<b>29.05</b>	<b>203.42</b>	<b>47.68</b>
V	<b>Profit / (loss) before exceptional items and tax (III-IV)</b>	<b>-1.07</b>	<b>-4.08</b>	<b>0.70</b>	<b>-2.23</b>	<b>0.82</b>
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit / (loss) before tax (V-VI)</b>	<b>-1.07</b>	<b>-4.08</b>	<b>0.70</b>	<b>-2.23</b>	<b>0.82</b>
VIII	Tax Expense:					
	(1) Current tax	0.62	0.00	0.25	1.42	0.25
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00
	<b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>	<b>-1.69</b>	<b>-4.08</b>	<b>0.45</b>	<b>-3.65</b>	<b>0.57</b>
IX						
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
XII	<b>Profit/(loss) from Discontinuing operations (after tax )(X-XI)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIII	<b>Profit / (Loss) for the period (IX+XII)</b>	<b>-1.69</b>	<b>-4.08</b>	<b>0.45</b>	<b>-3.65</b>	<b>0.57</b>
XIV	Other comprehensive income					
	A (i) Items that will not be reclassified to profit or loss					
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss					
	(ii) Income tax relating to items that will be reclassified to profit or loss					
XV	Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	-1.69	-4.08	0.45	-3.65	0.57
XVI	Earnings per equity share (for continuing operation):					
	(1) Basic	0.00	0.00	0.00	0.00	0.01
	(2) Diluted	0.00	0.00	0.00	0.00	0.01
XVII	Earnings per equity share (for discontinued operation):					
	(1) Basic					0.01
	(2) Diluted	0.00	0.00	0.00	0.00	0.01
XVIII	Earnings per equity share (for discontinued & continuing operation):					
	(1) Basic	0.00	0.00	0.00	0.00	0.01
	(2) Diluted	0.00	0.00	0.00	0.00	0.01
1	<b>NOTES:</b>					
2	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.					
3	The Segment - wise details are not applicable to the Company as the Company has only one segments.					
	Previous period's figures have been reclassified / regrouped, wherever necessary.					

For Rubra Medicaments Limited

Place: Mumbai  
Date:- May 25,2022

Abha Kapoor  
Director (Finance) & CFO  
DIN: 02799429

**RUBRA MEDICAMENTS LIMITED**

*(Rs. in Lakhs)*

**STATEMENT OF ASSETS AND LIABILITIES**

	Particulars	Figures as at the end of current reporting period	Figures as at the end of the previous reporting period
		31-Mar-22	31-Mar-21
		Audited	Audited
	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Property, plant and equipment	1.20	1.36
	(b) Capital work-in-progress	-	-
	(c) Investment property	-	-
	(d) Goodwill	-	-
	(e) Other intangible assets	-	-
	(f) Intangible assets under development	-	-
	(g) Biological assets other than bearer plants	-	-
	(h) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	-	-
	(iii) Loans	-	-
	(iv) Others (to be specified) - Advances	-	-
	(i) Deferred tax assets (net)	-	-
	(j) Other non-current assets	-	-
	<b>Total non-current assets</b>	<b>1.20</b>	<b>1.36</b>
<b>2</b>	<b>Current assets</b>		
	(a) Inventories	-	-
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	66.63	22.05
	(iii) Cash and cash equivalents	0.13	0.86
	(iv) Bank balances other than (iii) above	1.49	50.77
	(v) Loans	11.50	11.50
	(vi) Others to be specified	-	-
	(c) Current tax assets (net)	-	-
	(d) Other current assets	3.74	3.93
	<b>Total current assets</b>	<b>83.49</b>	<b>89.11</b>
	<b>Total assets</b>	<b>84.69</b>	<b>90.47</b>
<b>1</b>	<b>EQUITY AND LIABILITIES</b>		
	<b>Equity</b>		
	(a) Equity share capital	546.83	546.83
	(b) Other equity	-488.72	-485.06
	<b>Total equity</b>	<b>58.11</b>	<b>61.77</b>
	<b>LIABILITIES</b>		
<b>2</b>	<b>Non-current liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	-	-
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-
	(b) Provisions	-	-
	(c) Deferred tax liabilities (net)	0.04	0.04
	(d) Other non-current liabilities	-	-
	<b>Total non-current liabilities</b>	<b>0.04</b>	<b>0.04</b>
	<b>Current liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	0.06	0.12
	(iii) Other financial liabilities (other than those specified in item (a))	-	-
	(b) Other current liabilities		
	(c) Provisions, current	26.48	28.54
	(d) Current tax liabilities (Net)	-	-
	<b>Total current liabilities</b>	<b>26.54</b>	<b>28.66</b>
	<b>Total liabilities</b>	<b>26.58</b>	<b>28.70</b>
	<b>Total Equity and Liabilities</b>	<b>84.69</b>	<b>90.47</b>

For Rubra Medicaments Limited

Place: Mumbai  
Date:- May 25,2022

Abha Kapoor  
Director (Finance) & CFO  
DIN: 02799429

**RUBRA MEDICAMENTS LIMITED**

**CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2022**

	Particulars	March 31, 2022	March 31, 2021
		In Lakh	In Lakh
<b>A</b>	<b><u>Cash Flow From Operating Activities</u></b>		
	Net Profit before tax and Extraordinary Items	-2.23	0.81
	<b>Adjustment for :</b>		
	Depreciation	0.16	0.16
	Operating Profit before working Capital Changes	-2.07	0.97
	<b>Adjustment for Capital Changes:</b>		
	Increase/Decrease in Current Liabilities & Provisions	-2.06	14.48
	Increase/Decrease in Trade Payables	-0.06	0.12
	Increase/Decrease in Fixed Assets	-	-
	Increase/Decrease in Cash Loans and advances	0.19	29.28
	Increase/Decrease in Trade Receivables	-44.58	6.95
	Cash Generated From Operations	<b>-48.58</b>	<b>51.80</b>
	Income Tax / Deferred Tax Paid	1.42	0.25
	Extraordinary items	0.00	0.00
	<b><u>Net cash from Operating Activities</u></b>	<b>-50.00</b>	<b>51.55</b>
<b>B</b>	<b><u>Net Cash From Investing Activities</u></b>	-	-
<b>C</b>	<b><u>Net Cash Flow From Financing Activities</u></b>	-	-
	Net Increase (Decrease) in cash & cash equivalents (A+B+C)	<b>-50.00</b>	<b>51.55</b>
	Opening Balance of Cash & Cash Equivalents	51.63	0.08
	Closing Balance of Cash & Cash Equivalents	1.63	51.63

As per our Report of even date.

For and on behalf of Board of Director:  
Rubra Medicaments Limited

Mumbai  
Date: May 25, 2022

Abha Kapoor  
Director (Finance) & CFO  
DIN: 02799429